Viewing Study NCT00039000



Ignite Creation Date: 2024-05-05 @ 11:25 AM
Last Modification Date: 2024-10-26 @ 9:07 AM
Study NCT ID: NCT00039000
Status: COMPLETED
Last Update Posted: 2012-09-07
First Post: 2002-06-06

Brief Title: Study of Heat Shock Protein-Peptide Complex HSPPC-96 Versus IL-2DTIC for Stage IV Melanoma
Sponsor: Agenus Inc
Organization: Agenus Inc

Study Overview

Official Title: A Phase III Study of Heat Shock Protein-Peptide Complex HSPPC-96 Versus Physicians Choice Including Interleukin-2 andor DacarbazineTemozolomide-based Therapy andor Complete Tumor Resection in Stage IV Melanoma
Status: COMPLETED
Status Verified Date: 2012-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 HSPPC-96 or Oncophage after surgery live longer than people who may or may not have surgery but who receive conventional chemotherapy including IL-2DTIC A second goal is to determine the safety and frequency of side effects in subjects who receive therapy with HSPPC-96
Detailed Description: Primary Objective

To determine whether subjects with stage IV melanoma randomized to HSPPC-96 have longer survival than subjects randomized to physicians choice including interleukin-2 andor dacarbazinetemozolomide andor complete tumor resection

Secondary Objective

To determine frequency of adverse events in subjects randomized to HSPPC-96

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None